drugset / Trial / NCT00193271

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

NCT00193271

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.

Timeline

Start
2004-08
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule
Subject estramustine Other / unclassified

Indications